Apimeds Pharmaceuticals US, Inc. Logo

Apimeds Pharmaceuticals US, Inc.

Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.

APUS | US

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
100 MATAWAN RD, 7747 MATAWAN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Apimeds Pharmaceuticals US, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to treat inflammation and pain. The company's lead program is Apitox, a novel, non-narcotic therapy derived from purified honey bee venom. Apitox is being clinically studied for treating pain and inflammation, particularly in patients with osteoarthritis. Apimeds operates on a principle it calls 'Actual Intelligence (ai²™),' which emphasizes human experience, scientific rigor, and clinical judgment to identify and develop overlooked or distressed clinical assets. This approach guides the company in navigating regulatory, intellectual property, and market access challenges, with a primary commitment to patients and physicians.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Apimeds Pharmaceuticals US, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Apimeds Pharmaceuticals US, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Apimeds Pharmaceuticals US, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ObsEva SA Logo
Developed novel therapeutics for women's reproductive health and pregnancy.
Switzerland
OBSN
OCULAR THERAPEUTIX, INC Logo
Develops hydrogel drug delivery therapies for eye diseases like wet AMD and glaucoma.
United States of America
OCUL
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive topical therapies for ophthalmic diseases.
United States of America
OCS
ODI Pharma AB Logo
Distributes pharmaceutical medicinal cannabis products across Eastern Europe, with a focus on Poland.
Sweden
ODI
Olema Pharmaceuticals, Inc. Logo
A clinical-stage biopharma developing targeted therapies for women's cancers, focusing on breast cancer.
United States of America
OLMA
OliX Pharmaceuticals, Inc. Logo
Developing RNAi therapeutics for dermatology, ophthalmology, and metabolic diseases via an asiRNA platform.
South Korea
226950
OMEROS CORP Logo
Develops first-in-class therapeutics for challenging diseases with unmet medical needs.
United States of America
OMER
ONCODESIGN Logo
Developing precision oncology solutions for resistant and metastatic cancers.
France
ALONC
Oncodesign Precision Medicine S.A Logo
Develops precision therapies & diagnostics for resistant and metastatic cancers.
France
ALOPM
Oncoinvent ASA Logo
Developing alpha-emitting radiotherapies for treating cancers in the peritoneal cavity.
Norway
OCIN

Talk to a Data Expert

Have a question? We'll get back to you promptly.